Skip to main content

Peer Review reports

From: Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

Original Submission
12 Apr 2021 Submitted Original manuscript
20 Jul 2021 Reviewed Reviewer Report
17 Aug 2021 Reviewed Reviewer Report
13 Sep 2021 Author responded Author comments - Shogo Nakamoto
Resubmission - Version 2
13 Sep 2021 Submitted Manuscript version 2
2 Nov 2021 Reviewed Reviewer Report
2 Nov 2021 Reviewed Reviewer Report
20 Dec 2021 Author responded Author comments - Shogo Nakamoto
Resubmission - Version 3
20 Dec 2021 Submitted Manuscript version 3
Publishing
22 Dec 2021 Editorially accepted
3 Jan 2022 Article published 10.1186/s12885-021-09137-0

You can find further information about peer review here.

Back to article page